Overview

Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Naïve patients with chronic hepatitis C (CHC) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in Russia. The objective of this study is to examine the influence of insulin resistance on the safety and efficacy of treatment with pegylated interferon and ribavirin and to determine the prevalence of insulin resistance in different populations of CHC patients.
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Interferons
Ribavirin